Literature DB >> 24359236

Formononetin induces the mitochondrial apoptosis pathway in prostate cancer cells via downregulation of the IGF-1/IGF-1R signaling pathway.

Wen-Jun Huang1, Ling-Yun Bi, Zhen-Zhao Li, Xing Zhang, Yu Ye.   

Abstract

Abstract
Context: Formononetin, an isoflavone, can inhibit the proliferation of cancer cells, including those of the prostate. However, its antitumor mechanism remains unclear. Aim: To investigate whether the insulin-like growth factor 1 (IGF-1)/insulin-like growth factor 1 receptor (IGF-1 R) signaling pathway mediates the formononetin antitumor effect on prostate cancer cells. Materials and methods: The viability of PC-3 cells was measured by MTT assay 48 h after formononetin treatment (25, 50 and 100 μM). Formononetin-induced cell apoptosis was measured by Hoechst 33258 staining and flow cytometry. Expression of Bax mRNA was detected by real-time PCR, and the expression levels of Bax and IGF-1 R proteins were detected by western blots.
Results: At concentrations >12.5 μM, formononetin significantly inhibited the proliferation of human prostate cancer cells. Formononetin increased Bax mRNA and protein expression levels and decreased the expression levels of pIGF-1 R protein in a dose-dependent manner.
Conclusion: High concentrations of formononetin-induced apoptosis in androgen-independent prostate cancer cells through inhibition of the IGF-1/IGF-1 R pathway.

Entities:  

Year:  2013        PMID: 24359236     DOI: 10.3109/13880209.2013.842600

Source DB:  PubMed          Journal:  Pharm Biol        ISSN: 1388-0209            Impact factor:   3.503


  9 in total

1.  Formononetin suppresses the proliferation of human non-small cell lung cancer through induction of cell cycle arrest and apoptosis.

Authors:  Yi Yang; Yi Zhao; Xinghao Ai; Baijun Cheng; Shun Lu
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

2.  Prostate Cancer Therapy Using Docetaxel and Formononetin Combination: Hyaluronic Acid and Epidermal Growth Factor Receptor Targeted Peptide Dual Ligands Modified Binary Nanoparticles to Facilitate the in vivo Anti-Tumor Activity.

Authors:  Zhaoqiang Dong; Yuzhen Wang; Jing Guo; Chuan Tian; Wengu Pan; Hongwei Wang; Jieke Yan
Journal:  Drug Des Devel Ther       Date:  2022-08-11       Impact factor: 4.319

3.  Hyperoside protects human primary melanocytes against H2O2-induced oxidative damage.

Authors:  Bin Yang; Qin Yang; Xin Yang; Hong-Bo Yan; Qi-Ping Lu
Journal:  Mol Med Rep       Date:  2016-04-12       Impact factor: 2.952

4.  miR-223 contributes to the AGE-promoted apoptosis via down-regulating insulin-like growth factor 1 receptor in osteoblasts.

Authors:  Yi Qin; Jichao Ye; Peng Wang; Liangbin Gao; Suwei Wang; Huiyong Shen
Journal:  Biosci Rep       Date:  2016-04-05       Impact factor: 3.840

5.  The Extracts and Major Compounds Derived from Astragali Radix Alter Mitochondrial Bioenergetics in Cultured Cardiomyocytes: Comparison of Various Polar Solvents and Compounds.

Authors:  Yun Huang; Kenneth Kin Leung Kwan; Ka Wing Leung; Huaiyou Wang; Xiang Peng Kong; Tina Ting Xia Dong; Karl Wah Keung Tsim
Journal:  Int J Mol Sci       Date:  2018-05-25       Impact factor: 5.923

Review 6.  Formononetin: A Review of Its Anticancer Potentials and Mechanisms.

Authors:  Kai-Ching Tay; Loh Teng-Hern Tan; Chim Kei Chan; Sok Lai Hong; Kok-Gan Chan; Wei Hsum Yap; Priyia Pusparajah; Learn-Han Lee; Bey-Hing Goh
Journal:  Front Pharmacol       Date:  2019-07-26       Impact factor: 5.810

Review 7.  Phytochemicals in Inhibition of Prostate Cancer: Evidence from Molecular Mechanisms Studies.

Authors:  Qiongyu Hao; Yanyuan Wu; Jaydutt V Vadgama; Piwen Wang
Journal:  Biomolecules       Date:  2022-09-16

8.  Low concentration of formononetin promotes proliferation of estrogen receptor-positive cells through an ERα-miR-375-PTEN-ERK1/2-bcl-2 pathway.

Authors:  Yan-Hong Guo; Feng-Yan Tang; Yong Wang; Wen-Jun Huang; Jing Tian; Hui-Ling Lu; Min Xin; Jian Chen
Journal:  Oncotarget       Date:  2017-10-19

Review 9.  Focus on Formononetin: Anticancer Potential and Molecular Targets.

Authors:  Samantha Kah Ling Ong; Muthu K Shanmugam; Lu Fan; Sarah E Fraser; Frank Arfuso; Kwang Seok Ahn; Gautam Sethi; Anupam Bishayee
Journal:  Cancers (Basel)       Date:  2019-05-01       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.